Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 (anti-CTLA-4) plus sintilimab in advanced biliary tract cancer after standard therapy progression
CTR20223243Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IBI310, sintilimab in biliary cancer, sponsored by Innovent Biologics. Started Dec 2022; status: completed.
02
Drugs
IBI310sintilimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20223243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223243.